
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is expected to see growth in its key products, despite LOE headwinds and competitive pressures on certain drugs. The recent launches of Repatha, Aimovig, Lumakras, and Tezspire have exceeded expectations, contributing to increased long-term revenue estimates for these products. Additionally, their Uplizna product is positioned for success in the IgG4-RD and gMG markets, while their TSLP platform has potential for expansion and new treatments. Despite lower near-term estimates, Amgen is well-positioned for long-term success and remains actively seeking innovative opportunities.
Bears say
Amgen is facing potential headwinds from upcoming catalysts, including Phase 3 data on several key drugs in their pipeline, such as Dazodalibep for Sjogren's Syndrome and Tezspire for EoE, which are not expected until the second half of 2026. While the company has a strong portfolio of flagship drugs, the limited upside potential for their shares at their current valuation and the potential competition for MariTide's drugs in the diabetes market may also contribute to a negative outlook. The company's quarterly results were strong, leading to a slight decrease in their DCF-derived price target to $340, but we maintain a Neutral rating on the stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares